Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Passiglia

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Cancers|June 19, 2024
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging StrategiesGiorgia Ferrari, Benedetta Del Rio, Silvia Novello, et al.
Journal of Thoracic Disease|August 18, 2020
Improving lung cancer outcomes through smoking cessation: the Women Against Lung Cancer in Europe (WALCE) experienceEnrica Capelletto, Francesco Passiglia, Federica Ferraresi, et al.
Translational Lung Cancer Research|January 25, 2021
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature reviewGianmarco Leone, Francesco Passiglia, Paolo Bironzo, et al.
Translational Lung Cancer Research|July 23, 2021
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune diseaseFrancesco Passiglia, Valeria Cetoretta, Marco De Filippis, et al.
Journal of Thoracic Disease|June 29, 2018
Vaccine and immune cell therapy in non-small cell lung cancerHelena Oliveres, Christian Caglevic, Francesco Passiglia, et al.
Critical Reviews in Oncology/Hematology|January 19, 2016
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Translational Lung Cancer Research|June 13, 2022
Optimizing the clinical management of <i>EGFR</i>-mutant advanced non-small cell lung cancer: a literature reviewFrancesco Passiglia, Paolo Bironzo, Valentina Bertaglia, et al.
Pharmacology & Therapeutics|July 3, 2018
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitorsEnrico Bronte, Giuseppe Bronte, Giuseppina Novo, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
EGFR inhibition in NSCLC: New findings…. and opened questions?Francesco Passiglia, Angela Listì, Marta Castiglia, et al.
International Journal of Cancer|October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumabFrancesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Cancers|June 19, 2024
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging StrategiesGiorgia Ferrari, Benedetta Del Rio, Silvia Novello, et al.
Journal of Thoracic Disease|August 18, 2020
Improving lung cancer outcomes through smoking cessation: the Women Against Lung Cancer in Europe (WALCE) experienceEnrica Capelletto, Francesco Passiglia, Federica Ferraresi, et al.
Translational Lung Cancer Research|January 25, 2021
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature reviewGianmarco Leone, Francesco Passiglia, Paolo Bironzo, et al.
Translational Lung Cancer Research|July 23, 2021
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune diseaseFrancesco Passiglia, Valeria Cetoretta, Marco De Filippis, et al.
Journal of Thoracic Disease|June 29, 2018
Vaccine and immune cell therapy in non-small cell lung cancerHelena Oliveres, Christian Caglevic, Francesco Passiglia, et al.
Critical Reviews in Oncology/Hematology|January 19, 2016
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Translational Lung Cancer Research|June 13, 2022
Optimizing the clinical management of <i>EGFR</i>-mutant advanced non-small cell lung cancer: a literature reviewFrancesco Passiglia, Paolo Bironzo, Valentina Bertaglia, et al.
Pharmacology & Therapeutics|July 3, 2018
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitorsEnrico Bronte, Giuseppe Bronte, Giuseppina Novo, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
EGFR inhibition in NSCLC: New findings…. and opened questions?Francesco Passiglia, Angela Listì, Marta Castiglia, et al.
International Journal of Cancer|October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumabFrancesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Pageof 13